We've made it easier for you to connect! Fill out your NEW profile.
Breastcancer.org is hiring! Read the job posting: Virtual Support Group Facilitator and Community Moderator
Diagnosed Young? We'd love your answers to these questions.
Take our poll: What's one thing your body is teaching you this summer?
Lynparza Approved To Treat High-Risk, Early-Stage, HER2-, BRCA+
Options

moderators
Posts: 9,295
Lynparza Approved To Treat High-Risk, Early-Stage, HER2-Negative Breast Cancer With BRCA Mutation
Mar 13, 2022
The FDA approved Lynparza to treat early-stage, HER2-negative breast cancer with a BRCA1 or BRCA2 mutation and a high risk of recurrence, which also has been previously treated with chemotherapy — either before or after surgery. Read more...
0
Categories
Join Us on Zoom: Upcoming virtual support groups. Read more...
Share more about you! Fill out your NEW profile.
Breastcancer.org is hiring! Read the job posting: Virtual Support Group Facilitator and Community Moderator